Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.

Journal of lipid research - 1 Nov 2012

Ma Li, Ballantyne Christie M, Belmont John W, Keinan Alon, Brautbar Ariel

Abstract excerpt

The mixed dyslipidemia phenotype is characterized by elevated triglycerides (TG), low HDL cholesterol (HDL-C), increased ApoB levels, and premature coronary atherosclerosis. Fibrate-statin combination therapy reduces ApoB levels and coronary events in the mixed dyslipidemia population. We sought to identify gene-gene interactions that affect ApoB response to statin-fenofibric acid therapy in the mixed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiopoietin-Like Protein 3
Share to Angiopoietin-like Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiopoietins

Share to Atorvastatin

Share to Heptanoic Acids

Share to Pyrroles

Share to Rosuvastatin Calcium

Share to Simvastatin

Source

Open in PubMed Open full text

Identifiers

PMID: 22896670
DOI: 10.1194/jlr.M028829
PMCID: PMC3466010

Genes

ANGPTL3
RXRA
TG

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.PMID 22896670Read ↗

LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.Semantic proximity Read ↗

Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.Semantic proximity Read ↗

Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.Semantic proximity Read ↗

Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.Semantic proximity Read ↗

Gene-statin interaction study identifies 9 loci that moderate statin effectiveness in blood lipidsSemantic proximity Read ↗

Pharmacogenomics of cholesterol-lowering therapy.Semantic proximity Read ↗

A combination of proatherogenic single-nucleotide polymorphisms is associated with increased risk of coronary artery disease and myocardial infarction in Asian Indians.Semantic proximity Read ↗

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.Semantic proximity Read ↗

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.Semantic proximity Read ↗

A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies.Semantic proximity Read ↗

Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region.Semantic proximity Read ↗

Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.